- Home
- STTK vs HLP Comparison
STTK vs HLP Comparison
Compare STTK & HLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- HLP
- Stock Information
- Founded
- STTK 2016
- HLP 2021
- Country
- STTK United States
- HLP China
- Employees
- STTK N/A
- HLP N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- HLP Industrial Machinery/Components
- Sector
- STTK Health Care
- HLP Industrials
- Exchange
- STTK Nasdaq
- HLP Nasdaq
- Market Cap
- STTK 112.6M
- HLP 102.1M
- IPO Year
- STTK 2020
- HLP 2023
- Fundamental
- Price
- STTK $1.96
- HLP $1.71
- Analyst Decision
- STTK Hold
- HLP
- Analyst Count
- STTK 5
- HLP 0
- Target Price
- STTK $3.00
- HLP N/A
- AVG Volume (30 Days)
- STTK 162.8K
- HLP 89.1K
- Earning Date
- STTK 11-06-2025
- HLP 05-15-2026
- Dividend Yield
- STTK N/A
- HLP N/A
- EPS Growth
- STTK N/A
- HLP N/A
- EPS
- STTK N/A
- HLP 0.02
- Revenue
- STTK $1,000,000.00
- HLP $16,731,357.00
- Revenue This Year
- STTK N/A
- HLP N/A
- Revenue Next Year
- STTK N/A
- HLP N/A
- P/E Ratio
- STTK N/A
- HLP $80.07
- Revenue Growth
- STTK N/A
- HLP 19.13
- 52 Week Low
- STTK $0.69
- HLP $0.61
- 52 Week High
- STTK $2.71
- HLP $1.82
- Technical
- Relative Strength Index (RSI)
- STTK 49.33
- HLP 69.66
- Support Level
- STTK $1.86
- HLP $1.50
- Resistance Level
- STTK $2.06
- HLP $1.65
- Average True Range (ATR)
- STTK 0.14
- HLP 0.10
- MACD
- STTK -0.00
- HLP 0.01
- Stochastic Oscillator
- STTK 43.64
- HLP 97.62
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.